Table 2 Accompanied diseases and background therapies of subjects with and without SRC.
With SRC(n = 839) | Without SRC(n = 3786) | P-value | |
|---|---|---|---|
DPN (n, %) | 200, 23.8% | 832, 22.0% | 0.241 |
DR (n, %) | 196, 23.4% | 858, 22.7% | 0.662 |
DN (n, %) | 230, 27.4% | 786, 20.8% | <0.001 |
PVD (n, %) | 596, 71.0% | 2630, 69.5% | 0.370 |
Urolithiasis (n, %) | 115, 13.7% | 376, 9.9% | 0.001 |
Hypertension (n, %) | 542, 64.6% | 2073, 54.8% | <0.001 |
Hyperlipidemia (n, %) | 250, 29.8% | 1233, 32.6% | 0.120 |
Hypertriglyceridemia (n, %) | 93, 11.1% | 420, 11.1% | 0.739 |
Hypercholesterolemia (n, %) | 90, 10.7% | 444, 11.7% | 0.298 |
Combined hyperlipidemia (n, %) | 67, 8.0% | 369, 9.7% | 0.088 |
CHD (n, %) | 112, 13.3% | 453, 12.0% | 0.268 |
Stroke (n, %) | 107, 12.8% | 434, 11.5% | 0.293 |
Anti-diabetic drug users (n, %) | 772, 92.0% | 3416, 90.2% | 0.109 |
Monotherapy (n, %) | 184, 21.9% | 781, 20.6% | 0.091 |
Bitherapy (n, %) | 277, 33.0% | 1221, 32.3% | 0.129 |
Multitherapy (n, %) | 311, 37.1% | 1414, 37.3% | 0.185 |
Anti-hypertensive drug users (n, %) | 214, 39.5% | 808, 39.0% | 0.830 |
ACEI users (n, %) | 26, 4.8% | 107, 5.2% | 0.775 |
ARB users (n, %) | 188, 34.7% | 701, 33.8% | 0.743 |
